ClinicalTrials.gg
CompletedNCT02179671Updated Aug 2, 2019Results posted

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

A Phase 2 interventional study of Gefitinib and AZD9291 in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV), sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-08-02.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. Gefitinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
65th of 84
32 · median 65
Started
2014
with 5 others
Phase 2
43 of 87
none open now
Registered
75th of 87
by date
Lead sponsor
13 of 87
AstraZeneca

Among the 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung, this one is the 65th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2014, is one of 43 in phase 2, and was the 75th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About gefitinib

Gefitinib: first FDA approval 2003 (IRESSA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .

Read the detailed description

This is a multi-arm, multi-cohort, Phase IIa, open-label study of selected small molecules (gefitinib, AZD9291, or selumetinib + docetaxel) or 1st IMT (hereafter referred to as IMT-A; tremelimumab) followed by sequential switch to a 2nd IMT (hereafter referred to as IMT-B; MEDI4736) in locally advanced or metastatic NSCLC (Stage IIIB-IV). Patients will be enrolled concurrently into multiple cohorts.

03

Conditions studied

  • Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

Keywords

  • Lung cancer; NSCLC
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of archived tumor tissue sample and mandatory tissue
  • Patients must have either or cytologically documented NSCLC who present with locally advanced or stage IIIB-IV disease
  • ≥12 weeks
  • Patients must have and at least 1 lesion not previously irradiated
  • World Health Organization (WHO) performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Mixed small cell and NSCLC histology
  • Prior exposure to any or anti-PD-L1 antibody
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Gefitinib with a Seq. Switch to a MEDI4736

    Gefitinib once daily followed by MEDI4736

    Drug: Gefitinib

  • Experimental
    AZD9291 with a Seq. Switch to a MEDI4736

    AZD9291 once daily followed by MEDI4736

    Drug: AZD9291

  • Experimental
    Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736

    Selumetinib twice daily + docetaxel, followed by MEDI4736

    Drug: Selumetinib+Docetaxel

  • Experimental
    Tremelimumab with a Seq. Switch to a MEDI4736

    Tremelimumab every 4 weeks followed by MEDI4736

    Drug: Tremelimumab

Interventions

  • Gefitinib once daily followed by MEDI4736

  • AZD9291 once daily followed by MEDI4736

  • DrugSelumetinib+Docetaxel

    Drug pages: AZD 6244 · Docetaxel

    Selumetinib twice daily + docetaxel, followed by MEDI4736

  • Tremelimumab every 4 weeks followed by MEDI4736

This study also gives Durvalumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Confirmed Complete Response (CR) Rate

    To assess the efficacy of various sequences. CR (per RECIST 1.1 as assessed by the local/site Investigator) is defined as the disappearance of all target and non-target lesions. Confirmed complete response rate (CR rate) is defined as the number (%) of patients with a confirmed overall response of CR and was based on the evaluable analysis set.

    Time frame: Up to 2 years

Secondary outcomes

  1. Objective Response Rate (ORR)

    To further assess the efficacy of various sequences. Objective response rate (ORR; per RECIST 1.1 as assessed by the site Investigator) is defined as the number (%) of patients with a confirmed overall response of CR or PR and was based on the evaluable analysis set. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Up to 2 years

  2. Progression-free Survival

    Progression-free survival (per RECIST 1.1 as assessed by Investigator) is defined as the date of 1st dose of MEDI4736 until the date of objective disease progression or death. Progression of disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

    Time frame: Up to 2 years

  3. Duration of Response

    Duration of response (DoR; per RECIST 1.1 as assessed by the site Investigator) will be defined as the time from the date of 1st documented response (which is subsequently confirmed) until the 1st date of documented progression or death in the absence of disease progression.

    Time frame: Within 12 months

  4. Overall Survival

    To assess the efficacy of various sequences. In survival follow up at data cut off.

    Time frame: Up to 2 years

07

Results

Posted Aug 2, 2019

Participant flow

This study was conducted at 10 study centers in United States. The first subject was enrolled on 25 July 2014.

Participant flow — Overall Study
MilestoneGefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Started1121414
Completed00111
Not completed1111313

Outcome measures

PrimaryConfirmed Complete Response (CR) Rate

To assess the efficacy of various sequences. CR (per RECIST 1.1 as assessed by the local/site Investigator) is defined as the disappearance of all target and non-target lesions. Confirmed complete response rate (CR rate) is defined as the number (%) of patients with a confirmed overall response of CR and was based on the evaluable analysis set.

Time frame:
Up to 2 years
Reported as:
Number · patients (%)
Confirmed Complete Response (CR) Rate
patients (%)Gefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Confirmed Complete Response (CR) Rate———0 (NA to NA)0 (NA to NA)
SecondaryObjective Response Rate (ORR)

To further assess the efficacy of various sequences. Objective response rate (ORR; per RECIST 1.1 as assessed by the site Investigator) is defined as the number (%) of patients with a confirmed overall response of CR or PR and was based on the evaluable analysis set. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Up to 2 years
Reported as:
Number · patients (%)
Objective Response Rate (ORR)
patients (%)Gefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Objective Response Rate (ORR)———11.1 (1.2 to 36.8)0 (NA to NA)
SecondaryProgression-free Survival

Progression-free survival (per RECIST 1.1 as assessed by Investigator) is defined as the date of 1st dose of MEDI4736 until the date of objective disease progression or death. Progression of disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.

Time frame:
Up to 2 years
Reported as:
Number · patients
Progression-free Survival
patientsGefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Progression-free Survival———10
SecondaryDuration of Response

Duration of response (DoR; per RECIST 1.1 as assessed by the site Investigator) will be defined as the time from the date of 1st documented response (which is subsequently confirmed) until the 1st date of documented progression or death in the absence of disease progression.

Time frame:
Within 12 months
Reported as:
Median · Months
Duration of Response
MonthsGefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Duration of Response———NA—
SecondaryOverall Survival

To assess the efficacy of various sequences. In survival follow up at data cut off.

Time frame:
Up to 2 years
Reported as:
Number · patients
Overall Survival
patientsGefitinib With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Overall Survival———00

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gefitinib With a Seq. Switch to a MEDI4736—0/1 (0%)1/1 (100%)
Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736—1/2 (50%)2/2 (100%)
AZD9291 With a Seq. Switch to MEDI4736———
Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736—5/14 (35.7%)13/14 (92.9%)
Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736—8/13 (61.5%)13/13 (100%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventGefitinib With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
Atrial fibrillationCardiac disorders0/11/2—0/140/13
DiverticulitisInfections and infestations0/11/2—0/140/13
Enterocolitis infectiousInfections and infestations0/11/2—0/140/13
DehydrationMetabolism and nutrition disorders0/10/2—0/142/13
PneumoniaInfections and infestations0/10/2—2/141/13
Acute myocardial infarctionCardiac disorders0/10/2—0/141/13
Cardiac arrestCardiac disorders0/10/2—0/141/13
Pericardial effusionCardiac disorders0/10/2—0/141/13
Gastric ulcer haemorrhageGastrointestinal disorders0/10/2—0/141/13
NauseaGastrointestinal disorders0/10/2—0/141/13
Most frequent other events
Showing 10 of 138
Most frequent other events
EventGefitinib With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736AZD9291 With a Seq. Switch to MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736
ConstipationGastrointestinal disorders0/12/2—3/142/13
DiarrhoeaGastrointestinal disorders0/12/2—6/143/13
DyspepsiaGastrointestinal disorders0/12/2—1/140/13
VomitingGastrointestinal disorders0/12/2—4/143/13
FatigueGeneral disorders1/11/2—6/145/13
Upper respiratory tract infectionInfections and infestations1/10/2—0/140/13
Urinary tract infectionInfections and infestations1/10/2—2/141/13
HypomagnesaemiaMetabolism and nutrition disorders1/10/2—0/142/13
MyalgiaMusculoskeletal and connective tissue disorders0/12/2—0/140/13
HaematuriaRenal and urinary disorders1/10/2—1/140/13

Baseline characteristics

The 1 patient in the AZD9291 cohort was not dosed and no baseline data were recorded in the database. Because the AZD9291 with a Seq. Switch to a MEDI4736 arm had no data recorded during the study, this arm is not included in the reporting of adverse events.

Age, Continuous
Age, Continuous(Years)Gefitinib With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Total
Mean79.0 ± 065.0 ± 12.7357.8 ± 12.0564.3 ± 7.85—61.8 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Gefitinib With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Total
Female0164—11
Male1189—19
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Gefitinib With a Seq. Switch to a MEDI4736Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736AZD9291 With a Seq. Switch to a MEDI4736Total
White121211—23
Black or African American0022—4
08

Study locations

10 sites
  • Research Site
    Goodyear, Arizona 85338, United States
  • Research Site
    Washington, District of Columbia 20007, United States
  • Research Site
    Augusta, Georgia 30912, United States
  • Research Site
    Marietta, Georgia 30060, United States
  • Research Site
    Ashland, Kentucky 41101, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Mineola, New York 11501, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Spokane, Washington 99208-1129, United States
  • Research Site
    Tacoma, Washington 98405, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jun 2016, 22 months.

Results were first posted in Aug 2019, 3 years 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2014
First posted
Jul 2, 2014
StartActual
Jul 25, 2014
Primary completionActual
Jun 11, 2016
CompletionActual
Jun 11, 2016
Results first posted
Aug 2, 2019
Last update
Aug 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02179671
Lead sponsor
AstraZeneca
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Jul 2, 2014
Start date
Jul 25, 2014
Primary completion
Jun 11, 2016
Completion
Jun 11, 2016
Results posted
Aug 2, 2019
Last update
Aug 2, 2019

Study contacts

Samir N. Khleif, MD
principal investigator · International Coordinating Investigator

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gefitinib · Osimertinib · AZD 6244 · Docetaxel · Tremelimumab · Durvalumab

Start the discussion